Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Price:
1.075 USD
1.42%
Market Closed
Updated:
Apr 29, 2024
Adaptimmune Therapeutics PLC
Operating Income
|
Adaptimmune Therapeutics PLC
Operating Income Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Operating Income
-$130.7m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Operating Income
-$171.3m
|
CAGR 3-Years
-154%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Operating Income
-$175.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Operating Income
-$189.4m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Operating Income
-£59.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Operating Income
£53m
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
See Also
What is Adaptimmune Therapeutics PLC's Operating Income?
Operating Income
-130.7m
USD
-130.7m
USD
Based on the financial report for Dec 31, 2023, Adaptimmune Therapeutics PLC's Operating Income amounts to -130.7m USD.
What is Adaptimmune Therapeutics PLC's Operating Income growth rate?
Operating Income CAGR 5Y
-10%
-10%
Over the last year, the Operating Income growth was 19%. The average annual Operating Income growth rates for Adaptimmune Therapeutics PLC have been 1% over the past three years , -10% over the past five years .
You don't have any saved screeners yet
